Center for Drug Evaluation and Research Prescription Drug Labeling Improvement and Enhancement Initiative; Request for Comments and Information
Document ID: FDA-2013-N-0059-0001
Comments
Total: 15
-
Edward J. Fotsch - Comment
Posted : 03/20/2013 ID ：FDA-2013-N-0059-0002 Agency : FDA -
Mar 08,2013 11:59 PM ET
-
Association for Molecular Pathology (AMP) - Comment
Posted : 03/20/2013 ID ：FDA-2013-N-0059-0003 Agency : FDA -
Mar 08,2013 11:59 PM ET
-
Compressed Gas Association - Comment
Posted : 03/20/2013 ID ：FDA-2013-N-0059-0004 Agency : FDA -
Mar 08,2013 11:59 PM ET
-
Pharmaceutical Research and Manufacturers of America (PhRMA) - Comment
Posted : 03/20/2013 ID ：FDA-2013-N-0059-0005 Agency : FDA -
Mar 08,2013 11:59 PM ET
-
Merck & Co, Inc. - Comment
Posted : 03/20/2013 ID ：FDA-2013-N-0059-0006 Agency : FDA -
Mar 08,2013 11:59 PM ET
-
Baxter Healthcare Corporation - Comment
Posted : 03/20/2013 ID ：FDA-2013-N-0059-0007 Agency : FDA -
Mar 08,2013 11:59 PM ET
-
Lupus Foundation of Mid and Northern New York - Comment
Posted : 03/20/2013 ID ：FDA-2013-N-0059-0008 Agency : FDA -
Mar 08,2013 11:59 PM ET
-
Teva Pharmaceuticals - Comment
Posted : 03/20/2013 ID ：FDA-2013-N-0059-0009 Agency : FDA -
Mar 08,2013 11:59 PM ET
-
Janssen Research & Development - Comment
Posted : 03/20/2013 ID ：FDA-2013-N-0059-0010 Agency : FDA -
Mar 08,2013 11:59 PM ET
-
AbbVie - Comment
Posted : 03/20/2013 ID ：FDA-2013-N-0059-0011 Agency : FDA -
Mar 08,2013 11:59 PM ET
-
Eisai Inc. - Comment
Posted : 03/20/2013 ID ：FDA-2013-N-0059-0012 Agency : FDA -
Mar 08,2013 11:59 PM ET
-
Gordon Johnston Regulatory Consultants, LLC - Comment
Posted : 03/20/2013 ID ：FDA-2013-N-0059-0013 Agency : FDA -
Mar 08,2013 11:59 PM ET
-
Sandoz, Inc - Comment
Posted : 03/20/2013 ID ：FDA-2013-N-0059-0014 Agency : FDA -
Mar 08,2013 11:59 PM ET
-
GlaxoSmithKline (GSK) - Comment
Posted : 03/20/2013 ID ：FDA-2013-N-0059-0015 Agency : FDA -
Mar 08,2013 11:59 PM ET
-
Pfizer Inc - Comment
Posted : 03/20/2013 ID ：FDA-2013-N-0059-0016 Agency : FDA -
Mar 08,2013 11:59 PM ET